In the Boardroom
Refine Search
Biotechnology
US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
Anthony Harnden has been appointed as the new chair of the UK’s Medicine and Healthcare products Regulatory Agency (MHRA). 20 November 2024
Biotechnology
Mirai Bio has announced the appointment of Jens Vogel as the company’s president and chief operating officer (COO). 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Pharmaceutical
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Biotechnology
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
Biotechnology
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
Pharmaceutical
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
Biotechnology
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Biotechnology
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Biotechnology
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Biotechnology
US biotech major Biogen revealed it has appointed Daniel Quirk as chief medical officer and head of medical affairs. 29 October 2024
Pharmaceutical
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Biotechnology
AAVantgarde has announced the appointment of Lauren Kaskiel as chief business officer (CBO). 22 October 2024
Biotechnology
US privately-held immunotherapy company ImmunityBio has appointed Fabio Benedetti as chief strategy officer, effective January 4, 2021. 31 December 2020
Biotechnology
Swedish company Alligator Bioscience has appointed Christina Reimer as chief medical officer. 29 December 2020
Biotechnology
Swedish Orphan Biovitrum, also known as Sobi, has appointed Duane Barnes as the new head of Sobi in North America. 22 December 2020
Biotechnology
South Korean contract development and manufacturing organization Samsung Biologics says that John Rim will become its president and chief executive, with immediate effect. 17 December 2020
Pharmaceutical
Privately-held Danish medical dermatology specialist LEO Pharma today announced that Jörg Möller will join its global leadership team as executive vice president, global research and development, effective January 1, 2021. 16 December 2020
Pharmaceutical
Novo Seeds, the early-stage investment and company creation team of Novo Holdings, has invested in a new portfolio company Hemab ApS, which is focused on the development of bispecific antibodies for the treatment of rare bleeding disorders. 14 December 2020
Pharmaceutical
A veteran of both pharma and digital health has been named the chief executive of Cognito Therapeutics. 10 December 2020
Pharmaceutical
The WHO Foundation, a newly-formed independent grant-making foundation, has appointed Anil Soni as its first chief executive officer. 7 December 2020
Biotechnology
French immunotherapy specialist Transgene said yesterday that its board had approved the appointment of Hedi Ben Brahim as its new chairman and chief executive, effective January 1, 2021. 4 December 2020
Biotechnology
UK-based rare diseases specialist Mereo BioPharma today announced the appointment of Dr Suba Krishnan as senior vice president of clinical development, effective December 7, 2020. 23 November 2020
Pharmaceutical
The new head of the European Medicines Agency, Emer Cooke, has formally started work in the role, kicking off a five-year renewable mandate as executive director. 16 November 2020
Pharmaceutical
Boehringer Ingelheim said today it has recently welcomed Yew Looi Liew (YL) as the newly-appointed president of US Human Pharma at its US headquarters, Boehringer Ingelheim Pharmaceuticals based in Ridgefield, CT, which is the German family-owned drug major’s largest US subsidiary. 30 October 2020
Pharmaceutical
German pharma major Bayer has appointed Christian Rommel as the new head of R&D at its pharmaceuticals division. 27 October 2020
Pharmaceutical
EXUMA Biotech Corporation, the company discovering and developing CAR-T products and delivery solutions for liquid and solid tumors, has announced an update to its senior leadership team. 19 October 2020
Pharmaceutical
Germany’s Merck KGaA today announced that Dr Luciano Rossetti will be retiring as global head of R&D for the Healthcare business sector. 15 October 2020
Biotechnology
AffaMed Therapeutics today announced a definitive merger agreement with fellow Shanghai, China-based biopharmaceutical company EverInsight Therapeutics. 14 October 2020
Generics
UK-based medicines manufacturer and supplier Morningside Pharmaceuticals has appointed a new chief executive, with previous CEO Nik Kotecha to take on a strategic role and become chairman of the board. 7 October 2020
Pharmaceutical
US pharma giant Merck & Co on Friday announced that Roger Perlmutter will be retiring as executive vice president and president, Merck Research Laboratories (MRL). 5 October 2020
Biotechnology
Dr Daniel Vasella, former chairman and chief executive of Swiss pharma giant Novartis, has been appointed the new and independent chairman of the board of Swiss biotech Numab Therapeutics. 30 September 2020
Biotechnology
David Nicholson, the former executive vice president and chief R&D officer at Allergan, has been named chairman of the board of directors at UK-based Exscientia. 29 September 2020
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze